🏅 FDA Orphan Designation
Diacomit
stiripentol
Manufacturer: Biocodex
Indicated for:
Dravet syndromeOrphan
FDA-Approved Indications (1)
Dravet syndromeOrphan Designation
Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more
Indications & Usage
Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more ||| DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.
💙 Support Programs
View all →Diacomit
Biocodex
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.